ES2558030T3 - Método anticonceptivo oral multifásico de ciclo prolongado - Google Patents
Método anticonceptivo oral multifásico de ciclo prolongado Download PDFInfo
- Publication number
- ES2558030T3 ES2558030T3 ES07750352.2T ES07750352T ES2558030T3 ES 2558030 T3 ES2558030 T3 ES 2558030T3 ES 07750352 T ES07750352 T ES 07750352T ES 2558030 T3 ES2558030 T3 ES 2558030T3
- Authority
- ES
- Spain
- Prior art keywords
- equivalent amount
- estrogen
- phase
- ethinyl estradiol
- mcg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940127234 oral contraceptive Drugs 0.000 title 1
- 239000003539 oral contraceptive agent Substances 0.000 title 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 abstract 6
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 abstract 6
- 239000000262 estrogen Substances 0.000 abstract 6
- 229940011871 estrogen Drugs 0.000 abstract 6
- 229960002568 ethinylestradiol Drugs 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 5
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 abstract 3
- 229960001652 norethindrone acetate Drugs 0.000 abstract 3
- 239000000583 progesterone congener Substances 0.000 abstract 3
- 239000003433 contraceptive agent Substances 0.000 abstract 1
- 230000002254 contraceptive effect Effects 0.000 abstract 1
- 229940068196 placebo Drugs 0.000 abstract 1
- 239000000902 placebo Substances 0.000 abstract 1
- 230000003637 steroidlike Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/285—Arsenic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Una combinación multifásica y un kit anticonceptivo que comprende un envase que contiene: (a) de 7 a 14 dosificaciones diarias de una composición de Fase I que contiene un progestógeno en una cantidad equivalente de 0,3 a 1,5 mg de acetato de noretindrona y un estrógeno en una cantidad equivalente de 5 a 15 mcg de etinil estradiol; (b) de 14 a 22 dosificaciones diarias de una composición de Fase II que contiene un progestógeno en una cantidad equivalente de 0,3 a 1,5 mg de acetato de noretindrona y un estrógeno en una cantidad equivalente de 10 a 25 mcg de etinil estradiol; (c) de 20 a 31 dosificaciones diarias de una composición de Fase III que contiene un progestógeno en una cantidad equivalente de 0,3 a 1,5 mg de acetato de noretindrona y un estrógeno en una cantidad equivalente de 15 a 35 mcg de etinil estradiol; y (d) de 2 a 8 dosificaciones diarias de una composición de Fase IV, que contiene i. un estrógeno en una cantidad equivalente de 5 a 20 mcg de etinil estradiol, o ii. un placebo o un componente no esteroideo, o iii. una combinación de i. e ii., donde la cantidad equivalente de etinil estradiol de estrógeno en cada una de las Fases II y III sucesivas es al menos 5 mcg mayor que la cantidad equivalente de etinil estradiol de estrógeno en la fase inmediatamente anterior y donde las dosificaciones combinadas de las composiciones de Fase I, II, III y IV en el kit son de 54 a 58.
Description
Claims (1)
-
imagen1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77806706P | 2006-03-02 | 2006-03-02 | |
| US778067P | 2006-03-02 | ||
| US79265306P | 2006-04-18 | 2006-04-18 | |
| US792653P | 2006-04-18 | ||
| PCT/US2007/003508 WO2007106264A2 (en) | 2006-03-02 | 2007-02-09 | Extended cycle multiphasic oral contraceptive method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2558030T3 true ES2558030T3 (es) | 2016-02-01 |
Family
ID=38229300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07750352.2T Active ES2558030T3 (es) | 2006-03-02 | 2007-02-09 | Método anticonceptivo oral multifásico de ciclo prolongado |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8063030B2 (es) |
| EP (1) | EP1993531B1 (es) |
| CA (1) | CA2640520C (es) |
| ES (1) | ES2558030T3 (es) |
| IL (1) | IL193013A (es) |
| MX (1) | MX2008011074A (es) |
| SG (1) | SG172654A1 (es) |
| WO (1) | WO2007106264A2 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1878558A (zh) * | 2003-11-14 | 2006-12-13 | 沃纳奇尔科特公司 | 梯度雌激素避孕药 |
| US20070111975A1 (en) * | 2004-10-07 | 2007-05-17 | Duramed Pharmaceuticals, Inc. | Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| RS62297B1 (sr) | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| WO2013090117A1 (en) | 2011-12-13 | 2013-06-20 | Arstat, Inc. | A multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| RS57328B1 (sr) | 2015-06-18 | 2018-08-31 | Mithra Pharmaceuticals S A | Orodisperzibilna dozna jedinica koja sadrži estetrolsku komponentu |
| WO2016203044A1 (en) | 2015-06-18 | 2016-12-22 | Mithra Pharmaceuticals S.A. | Orodispersible tablet containing estetrol |
| LT3310345T (lt) | 2015-06-18 | 2021-06-25 | Estetra Sprl | Burnoje disperguojama tabletė, turinti estetrolio |
| NZ737945A (en) | 2015-06-18 | 2023-06-30 | Estetra Sprl | Orodispersible dosage unit containing an estetrol component |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| CR20200486A (es) | 2018-04-19 | 2021-01-27 | Estetra Sprl | Compuestos y sus usos para aliviar los síntomas asociados a la menopausa |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE35724E (en) * | 1982-04-28 | 1998-02-03 | Bio-Technology General Corp. | Contraception system and method |
| US4962098A (en) | 1987-06-15 | 1990-10-09 | Warner-Lambert Company | Graduated estrogen contraceptive |
| US5010070A (en) * | 1987-06-15 | 1991-04-23 | Warner-Lambert Company | Graduated estrogen contraceptive |
| DE4313926A1 (de) * | 1993-04-28 | 1994-11-03 | Jenapharm Gmbh | Pharmazeutisches Mehrphasenpräparat zur hormonalen Kontrazeption |
| DE4411585A1 (de) * | 1994-03-30 | 1995-10-05 | Schering Ag | Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption |
| DE19525017A1 (de) | 1995-06-28 | 1997-01-02 | Schering Ag | Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption |
| DE19531936A1 (de) | 1995-08-17 | 1997-02-20 | Schering Ag | Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend |
| DE19540253C2 (de) * | 1995-10-28 | 1998-06-04 | Jenapharm Gmbh | Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene |
| ES2229378T3 (es) | 1996-07-26 | 2005-04-16 | Wyeth | Anticonceptivo oral. |
| US5898032A (en) | 1997-06-23 | 1999-04-27 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy |
| US6251956B1 (en) | 1998-08-20 | 2001-06-26 | Ortho Pharmaceutical Corporation | Combination progestin oral contraceptive regimen |
| DE19739916C2 (de) | 1997-09-11 | 2001-09-13 | Hesch Rolf Dieter | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
| CA2448271A1 (en) | 2001-05-23 | 2002-11-28 | Panterhei Bioscience B.V. | Means and method for hormonal contraception |
| MXPA04005445A (es) | 2001-12-05 | 2005-03-23 | Barr Lab Inc | Anticonceptivos orales para prevenir el embarazo y disminuir la sintomatologia premenstrual. |
| JP2005519962A (ja) | 2002-03-11 | 2005-07-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | スルファターゼを阻害する継続的プロゲストゲン避妊レジメン |
| US20030219471A1 (en) | 2002-03-11 | 2003-11-27 | Caubel Patrick Michel | Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens |
| US20040142914A1 (en) | 2002-03-11 | 2004-07-22 | Friedman Andrew Joseph | Extended transdermal contraceptive regimens |
| JP2006525358A (ja) | 2003-05-02 | 2006-11-09 | ドゥラメド ファーマシューティカルズ， インコーポレイテッド | 長期周期避妊養生法を利用するホルモン治療の方法 |
| NZ585546A (en) | 2003-07-16 | 2011-10-28 | Teva Womens Health Inc | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
| JP2007507534A (ja) | 2003-10-01 | 2007-03-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 持続的三相避妊方法 |
| CN1878558A (zh) | 2003-11-14 | 2006-12-13 | 沃纳奇尔科特公司 | 梯度雌激素避孕药 |
| US20050113350A1 (en) * | 2003-11-26 | 2005-05-26 | Bernd Duesterberg | Extended use combination comprising estrogens and progestins |
| EP1735056B1 (en) | 2004-03-19 | 2012-10-24 | Warner Chilcott Company, LLC | Extended cycle multiphasic oral contraceptive method |
| DE102004019743B4 (de) | 2004-04-20 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens |
| MXPA06013195A (es) * | 2004-05-14 | 2007-02-14 | Irm Llc | Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar). |
| CA2609336C (en) | 2005-06-29 | 2013-12-10 | Warner Chilcott Company, Inc. | Quadraphasic continuous graduated estrogen contraceptive |
-
2007
- 2007-02-09 ES ES07750352.2T patent/ES2558030T3/es active Active
- 2007-02-09 SG SG2011039344A patent/SG172654A1/en unknown
- 2007-02-09 CA CA2640520A patent/CA2640520C/en active Active
- 2007-02-09 WO PCT/US2007/003508 patent/WO2007106264A2/en not_active Ceased
- 2007-02-09 EP EP07750352.2A patent/EP1993531B1/en active Active
- 2007-02-09 US US11/704,307 patent/US8063030B2/en active Active
- 2007-02-09 MX MX2008011074A patent/MX2008011074A/es active IP Right Grant
-
2008
- 2008-07-24 IL IL193013A patent/IL193013A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| MX2008011074A (es) | 2008-09-10 |
| US20070207945A1 (en) | 2007-09-06 |
| IL193013A (en) | 2011-11-30 |
| WO2007106264A2 (en) | 2007-09-20 |
| CA2640520C (en) | 2014-04-22 |
| CA2640520A1 (en) | 2007-09-20 |
| EP1993531A2 (en) | 2008-11-26 |
| WO2007106264A3 (en) | 2008-05-02 |
| SG172654A1 (en) | 2011-07-28 |
| EP1993531B1 (en) | 2015-10-14 |
| US8063030B2 (en) | 2011-11-22 |
| IL193013A0 (en) | 2009-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2008011074A (es) | Metodo anticonceptivo oral multifasico de ciclo prolongado. | |
| ES2399105T3 (es) | Anticonceptivo estrogénico cuadrifásico graduado de manera continua | |
| RS50262B2 (sr) | Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva | |
| JP2007535519A5 (es) | ||
| EA200900491A1 (ru) | Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола | |
| RU2009120528A (ru) | Способы гормональной терапии возрастающими дозами в режиме пролонгированного цикла | |
| CA2542854A1 (en) | Graduated estrogen contraceptive | |
| RU2007148080A (ru) | Составы и способы для лечения симптомов, связанных с циклом | |
| JP2005516913A5 (es) | ||
| AR049112A1 (es) | Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrual | |
| JP2010539153A5 (es) | ||
| MX2007013137A (es) | Regimen anticonceptivo con dosificacion de estrogeno ampliada. | |
| AR049197A1 (es) | Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona | |
| CY1108265T1 (el) | Στερεη διαστοματικη φαρμακευτικη μορφη για αντισυλληψη | |
| WO2005092441A3 (en) | Extended cycle multiphasic oral contraceptive method | |
| RS51434B (sr) | Višefazni preparat za kontracepciju na bazi prirodnog estrogena | |
| AR049196A1 (es) | Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona | |
| NO20072687L (no) | Farmasoytisk prevensjonspreparat | |
| HRP20090256T1 (en) | Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method | |
| DOP2006000037A (es) | Forma farmacológica peroral sólida para la anticoncepción | |
| DOP2007000122A (es) | Forma farmacologica peroral para anticoncepcion | |
| PL1937274T3 (pl) | Zastosowanie walerianianu estradiolu w połączeniu z dienogestem do doustnej terapii dysfunkcyjnego krwawienia macicznego wraz z doustną antykoncepcją | |
| TH84327B (th) | การใช้และชุดสำเร็จรูปแอนโดรเจนสเตอรอยด์ (Androgenic Steriod) แบบที่ไม่ใช้รับประทานในสุภาพสตรี |